The combination of PF-04449913 with another second generation TKI, Dasatinib, has also been shown to selectively inhibit engraftment of primary Lin−CD34+CD38+ CML LSCs in Rag2−/−gc−/− mice and to eradicate the formation of myeloid sarcomas [62]. The gene discussed is CD38; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.